The Medicines Co. Names Mark Timney As CEO In A Shakeup

CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.

Business reengineering

CEO Clive Meanwell has been with The Medicines Co. (TMC) for 22 years, most of that as its CEO, but as its search for a new identity in recent years has dragged on, the firm’s board of directors apparently determined that new leadership was necessary. Mark Timney, formerly the CEO of Purdue Pharma LP, will succeed Meanwell, although the long-time CEO will remain with the company as chief innovation officer.

TMC announced the change Dec. 11. Board Chairman Alex Denner, an activist investor, said the company’s focus will be on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip